EUVIMEDEUVIMED entdecken
Crossref

L26/P-062 Safety Evaluation of Hyperspectral Imaging of Individual Spermatozoa and Oocytes during ICSI: Analysis of Early Embryological Outcomes before Clinical Implementation

R. Trinidad Lahoz, R.M. Pacheco-Rendón, D. Muñoz Pellicer, M. Gil Juliá, J.M. De Los Santos, L. Mossetti, M.J. De Los Santos, R. Rivera Egea, N. Garrido

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.398 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von R. Trinidad Lahoz und 8 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Does the acquisition of hyperspectral images of live sperm and oocytes during ICSI affect fertilization and early embryo development outcomes? Summary answer Hyperspectral imaging during ICSI did not affect fertilization or embryo development, supporting its biological safety and feasibility for future AI-based sperm assessment. What is known already Advanced imaging technologies such as hyperspectral imaging (HS) are emerging as non-invasive tools for gamete assessment, providing biochemical and structural information beyond standard microscopy. Our group has previously reported promising results using HS-based algorithms to predict fertilization and embryo development, with model precision exceeding routine laboratory success rates. However, these findings are not yet definitive and require further validation. Before clinical translation, despite previous evidence demonstrating the biological safety of HS, it remains essential to evaluate its safety including both spermatozoa and oocytes. More preclinical studies are needed to confirm that HS can be safely integrated without compromising reproductive outcomes. Study design, size, duration Prospective interventional study including 24 patients undergoing oocyte donation cycles, using both fresh or vitrified oocytes, and autologous ejaculate sperm. A sibling oocyte design was conducted, with oocytes from the same cohort equally divided and randomly assigned to either standard or hyperspectral ICSI (HS-ICSI). HS-ICSI followed the standard workflow, with the addition of hyperspectral image acquisition of oocytes before microinjection and of spermatozoa after immobilization, immediately prior to microinjection. Data were collected August 2025-January 2026. Participants/materials, setting, methods Images were acquired using a 4200M Microscope system coupled to an IX73 inverted microscope and TruScope v.1.17 software. Outcomes included fertilization, usable, and good-quality blastocyst rates, with full gamete and embryo traceability. All rates were calculated per microinjected oocytes. To ensure robustness and account for paired and clustered data, analyses combined complementary methods: paired Wilcoxon tests, binomial GLM, GEE and GLMM with patient-level random effects. An intra-patient permutation test was performed as sensitivity analysis. Main results and the role of chance A total of 270 oocytes were microinjected, of which 132 underwent hyperspectral imaging prior to ICSI. Fertilization rates were 83.3% (95% CI 77.1–89.6%) in the standard ICSI group and 75.0% (67.6–82.4%) in the HS-ICSI group. No significant differences were observed using paired Wilcoxon signed-rank tests (p = 0.105), intra-patient permutation tests (p = 0.144), binomial generalized linear models (GLM, p = 0.093), or generalized estimating equations (GEE, p = 0.117). In generalized linear mixed-effects models (GLMM) accounting for patient-level clustering, a modest but statistically significant reduction in fertilization was detected (OR 0.615, 0.409–0.925, p = 0.019). Usable blastocyst rates were 53.6% (45.3–61.9%) in the control group versus 46.2% (37.7–54.7%) in the HS-ICSI group, with no significant differences across Wilcoxon (p = 0.255), permutation (p = 0.239), GLM (p = 0.224), GEE (p = 0.153), and GLMM (OR 0.733, 0.513–1.047, p = 0.088). Good-quality blastocyst rates were 40.6% (32.4–48.8%) versus 36.4% (28.2–44.6%), with no significant differences in any analysis (Wilcoxon p = 0.455; permutation p = 0.507; GLM p = 0.477; GEE p = 0.422; GLMM OR 0.836, 0.578–1.209, p = 0.341). Overall, results were consistent across outcomes and analytical approaches, indicating no robust or clinically meaningful impairment of fertilization or early embryo development following hyperspectral sperm imaging. Limitations, reasons for caution This study is limited by its sample size and exploratory nature, which may reduce statistical power and contribute to variability across analytical models. Although multiple complementary methods were applied, findings, particularly those observed in a single model, should be interpreted cautiously until confirmed in larger prospective cohorts. Wider implications of the findings Hyperspectral imaging for sperm and oocyte analysis is safe, showing no clinically meaningful impact on fertilization or blastocyst development. Beyond safety, these fingerprints provide a foundation for AI-based sperm prioritisation and decision-support tools, supporting integration of hyperspectral imaging into assisted reproduction laboratories without compromising gamete competence or embryo developmental potential. Trial registration number No

Zitieren

APA

Lahoz, R. T., Pacheco-Rendón, R., Pellicer, D. M., Juliá, M. G., Santos, J. D. L., Mossetti, L., Santos, M. D. L., Egea, R. R., & Garrido, N. (2026). L26/P-062 Safety Evaluation of Hyperspectral Imaging of Individual Spermatozoa and Oocytes during ICSI: Analysis of Early Embryological Outcomes before Clinical Implementation. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.398

Vancouver

Lahoz RT, Pacheco-Rendón R, Pellicer DM, Juliá MG, Santos JDL, Mossetti L, et al. L26/P-062 Safety Evaluation of Hyperspectral Imaging of Individual Spermatozoa and Oocytes during ICSI: Analysis of Early Embryological Outcomes before Clinical Implementation. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.398

BibTeX
@article{Lahoz2026,
  author = {Lahoz, R. Trinidad and Pacheco-Rendón, R.M. and Pellicer, D. Muñoz and Juliá, M. Gil and Santos, J.M. De Los and Mossetti, L. and Santos, M.J. De Los and Egea, R. Rivera and Garrido, N.},
  title = {L26/P-062 Safety Evaluation of Hyperspectral Imaging of Individual Spermatozoa and Oocytes during ICSI: Analysis of Early Embryological Outcomes before Clinical Implementation},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.398}
}
Kostenlos starten →